AIMS/HYPOTHESIS: Vascular endothelial growth factor (VEGF) has been recognised by loss-of-function experiments as a pleiotropic factor with importance in embryonic pancreas development and postnatal beta cell function. Chronic, nonconditional overexpression of VEGF-A has a deleterious effect on beta cell development and function. We report, for the first time, a conditional gain-of-function study to evaluate the effect of transient VEGF-A overexpression by adult pancreatic beta cells on islet vasculature and beta cell proliferation and survival, under both normal physiological and injury conditions. METHODS: In a transgenicmouse strain, overexpressing VEGF-A in a doxycycline-inducible and beta cell-specific manner, we evaluated the ability of VEGF-A to affect islet vessel density, beta cell proliferation and protection of the adult beta cell mass from toxin-induced injury. RESULTS: Short-term VEGF-A overexpression resulted in islet hypervascularisation, increased beta cell proliferation and protection from toxin-mediated beta cell death, and thereby prevented the development of hyperglycaemia. Extended overexpression of VEGF-A led to impaired glucose tolerance, elevated fasting glycaemia and a decreased beta cell mass. CONCLUSIONS/ INTERPRETATION: Overexpression of VEGF-A in beta cells time-dependently affects glycometabolic control and beta cell protection and proliferation. These data nourish further studies to examine the role of controlled VEGF delivery in (pre)clinical applications aimed at protecting and/or restoring the injured beta cell mass.
AIMS/HYPOTHESIS: Vascular endothelial growth factor (VEGF) has been recognised by loss-of-function experiments as a pleiotropic factor with importance in embryonic pancreas development and postnatal beta cell function. Chronic, nonconditional overexpression of VEGF-A has a deleterious effect on beta cell development and function. We report, for the first time, a conditional gain-of-function study to evaluate the effect of transient VEGF-A overexpression by adult pancreatic beta cells on islet vasculature and beta cell proliferation and survival, under both normal physiological and injury conditions. METHODS: In a transgenicmouse strain, overexpressing VEGF-A in a doxycycline-inducible and beta cell-specific manner, we evaluated the ability of VEGF-A to affect islet vessel density, beta cell proliferation and protection of the adult beta cell mass from toxin-induced injury. RESULTS: Short-term VEGF-A overexpression resulted in islet hypervascularisation, increased beta cell proliferation and protection from toxin-mediated beta cell death, and thereby prevented the development of hyperglycaemia. Extended overexpression of VEGF-A led to impaired glucose tolerance, elevated fasting glycaemia and a decreased beta cell mass. CONCLUSIONS/ INTERPRETATION: Overexpression of VEGF-A in beta cells time-dependently affects glycometabolic control and beta cell protection and proliferation. These data nourish further studies to examine the role of controlled VEGF delivery in (pre)clinical applications aimed at protecting and/or restoring the injured beta cell mass.
Authors: Christophe E Pierreux; Sabine Cordi; Anne-Christine Hick; Younes Achouri; Carmen Ruiz de Almodovar; Pierre-Paul Prévot; Pierre J Courtoy; Peter Carmeliet; Frédéric P Lemaigre Journal: Dev Biol Date: 2010-08-31 Impact factor: 3.582
Authors: Marcela Brissova; Alena Shostak; Masakazu Shiota; Peter O Wiebe; Greg Poffenberger; Jeannelle Kantz; Zhongyi Chen; Chad Carr; W Gray Jerome; Jin Chen; H Scott Baldwin; Wendell Nicholson; David M Bader; Thomas Jetton; Maureen Gannon; Alvin C Powers Journal: Diabetes Date: 2006-11 Impact factor: 9.461
Authors: Jose Mellado-Gil; Taylor C Rosa; Cem Demirci; Jose A Gonzalez-Pertusa; Silvia Velazquez-Garcia; Sara Ernst; Shelley Valle; Rupangi C Vasavada; Andrew F Stewart; Laura C Alonso; Adolfo Garcia-Ocaña Journal: Diabetes Date: 2010-10-27 Impact factor: 9.461
Authors: Willem Staels; Yannick Verdonck; Yves Heremans; Gunter Leuckx; Sofie De Groef; Carlo Heirman; Eelco de Koning; Conny Gysemans; Kris Thielemans; Luc Baeyens; Harry Heimberg; Nico De Leu Journal: Diabetologia Date: 2018-05-22 Impact factor: 10.122
Authors: E Hajizadeh-Saffar; Y Tahamtani; N Aghdami; K Azadmanesh; M Habibi-Anbouhi; Y Heremans; N De Leu; H Heimberg; P Ravassard; M A Shokrgozar; H Baharvand Journal: Sci Rep Date: 2015-03-30 Impact factor: 4.379
Authors: Anja Brboric; Svitlana Vasylovska; Jonna Saarimäki-Vire; Daniel Espes; José Caballero-Corbalan; Gunnar Larfors; Timo Otonkoski; Joey Lau Journal: Ups J Med Sci Date: 2019-10-18 Impact factor: 2.384